MONTREAL, QUEBEC--(Marketwire - June 25, 2008) - ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) announced today that it has further confirmed the efficacy of the prion capture resins developed by Pathogen Removal and Diagnostic Technologies Inc. (“PRDT”)’ in the removal of prions from different solutions, including mixtures of proteins containing high concentrations of specific proteins such as 25% albumin and 3% immunoglobulin solutions without affecting the concentration of the proteins. Plasma-derived albumin and immunoglobulin proteins are commonly used as therapeutics. Furthermore, proteins such as albumin are also regularly used as non-active stabilizing ingredients in the formulation of biopharmaceutical products.
